Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.

Research & Drug Development

Partners

In 2006, Newron signed an agreement with Merck Serono giving them exclusive worldwide rights to develop, manufacture and commercialise safinamide in Parkinson’s disease (PD), Alzheimer’s disease, and other therapeutic applications.  For more details, see “Media”, “Press Releases”.